Report #2863279

Received Oct 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Sep 13, 2025
Onset: Sep 13, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	AE435	—

Symptoms (1)

Extra dose administered

Symptom narrative

A patient received 2 doses of Arexvy.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 77-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number AE435, expiry date 30-OCT-2025) for prophylaxis. Previously administered products included Arexvy (1st dose was given in 2023). On 13-SEP-2025, the patient received the 2nd dose of Arexvy. On 13-SEP-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: A patient received 2 doses of Arexvy.). The outcome of the extra dose administered was not applicable. Additional Information: GSK receipt date: 16-SEP-2025 The reporter called to report that a patient received two doses of Arexvy. The reporter wanted to know was there any concerns and possible side effects.